Lalonde
Jean-Philippe Lalonde, Subiaco AU
Patent application number | Description | Published |
---|---|---|
20100239649 | Tumor Suppressor Factor - The present invention relates to a tumour suppressor gene, termed HLS-5 and the amino acid sequence that it encodes. The present invention also relates to the use of HLS-5 in regulating cell growth. | 09-23-2010 |
Jean-Philippe Lalonde, Western Australia AU
Patent application number | Description | Published |
---|---|---|
20090258827 | Transcription Factor Modulator - The present invention relates to novel agents that are useful for modulating transcription factor activity. In particular, the present invention relates to A transcription factor modulator comprising (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof or pharmaceutical composition thereof; or (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof. | 10-15-2009 |
20100048450 | Sumoylation Control Agent and Uses Thereof - The present invention relates to novel agents that are useful for controlling sumoylation. In particular, the present invention relates to a sumoylation control agent comprising: (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof, or pharmaceutical composition thereof; or (ii) a compound or composition capable of modulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof. | 02-25-2010 |
Jean-Philippe Lalonde, Shenton Park AU
Patent application number | Description | Published |
---|---|---|
20120164658 | Transcription Factor Modulator - The present invention relates to novel agents that are useful for modulating transcription factor activity. In particular, the present invention relates to a transcription factor modulator comprising (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof or pharmaceutical composition thereof or (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof. | 06-28-2012 |
20130330738 | Sumoylation Control Agent and Uses Thereof - The present invention relates to novel agents that are useful for controlling sumoylation. In particular, the present invention relates to a sumoylation control agent comprising: (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof, or a pharmaceutical composition thereof; or (ii) a compound or composition capable of modulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof. | 12-12-2013 |
20140127234 | Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof - The present invention relates to novel agents that are useful for treating hormone-dependent disorders. In particular, the present invention relates to A method of modulating a nuclear receptor in vivo comprising the step of administering to a subject in need thereof nuclear receptor modulating agent comprising a compound or composition capable of altering the endogenous levels of HLS-5 or its activity. | 05-08-2014 |
Jean-Phillippe Lalonde, Western Australia AU
Patent application number | Description | Published |
---|---|---|
20100215637 | Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof - The present invention relates to novel agents that are useful for treating hormone-dependent disorders. In particular, the present invention relates to A method of modulating a nuclear receptor in vivo comprising the step of administering to a subject in need thereof A nuclear receptor modulating agent comprising a compound or composition capable of altering the endogenous levels of HLS-5 or its activity. | 08-26-2010 |